SDT-201 was our first Phase 1/2 dose-escalation study examining the safety, pharmacokinetics, and preliminary efficacy of ascending drug and energy dose combinations for sonodynamic therapy using SONALA-001 in combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in subjects with diffuse intrinsic pontine glioma (DIPG).

15 DIPG subjects have been treated to date. The results are being analyzed for presentation and publication.

This trial identified the Recommended Phase 2 Dose of ultrasound energy for a subsequent clinical trial in DIPG.